Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8536894 | Pharmacology & Therapeutics | 2018 | 30 Pages |
Abstract
Several neurotropic cytokines relay their signaling through the leukemia inhibitory factor receptor. This 190Â kDa subunit couples with the 130Â kDa gp130 subunit to transduce intracellular signaling in neurons and oligodendrocytes that leads to expression of genes associated with neurosurvival. Moreover, activation of this receptor alters the phenotype of immune cells to an anti-inflammatory one. Although cytokines that activate the leukemia inhibitory factor receptor have been studied in the context of neurodegenerative disease, therapeutic targeting of the specific receptor subunit has been understudied in by comparison. This review examines the role of this receptor in the CNS and immune system, and its application in the treatment in stroke and other brain pathologies.
Keywords
GPiLIFTregsgp130CT-1EAEOPCLBPCNTFPBMCNSCOSMJanus kinasebrain injuryexperimental allergic encephalomyelitisinflammationoncostatin MPeripheral blood mononuclear cellNeural stem cellOligodendrocyte progenitor cellCytokineleukemia inhibitory factorciliary neurotrophic factorRegulatory T lymphocytesSignal transductionJAKcardiotrophin-1glycosyl-phosphatidylinositol
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Stephanie M. Davis, Keith R. Pennypacker,